An observational study in Acute Coronary Syndrome, STEMI and Coronary Occlusion, sponsored by Powerful Medical. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Powerful Medical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Acute Coronary Syndrome with a site in Austria — 3 open to participants now, 3 under way, none of them phase 3. Acute Coronary Syndrome · Austria.
Among the 34 studies in Acute Coronary Syndrome with a site in Austria, this one is one of 3 that started in 2024, is one of 8 observational ones, and was the 32nd registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →3 of the 34 studies in Acute Coronary Syndrome with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+
Pensionsversicherungsanstalt · Sites in Austria
Ages 18+
RobotDreams GmbH · Sites in Austria
Ages 18+ · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 718 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 3,271 across the 26 interventional studies, 859 across the 8 observational. Of the 28 that completed or were terminated, 12 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 34 have an industry lead sponsor. The 10 most frequent:
Powerful Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
Powerful Medical has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Acute Coronary Syndrome with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AI ECG TIMI is an investigator-initiated, international, and multicenter registry of acute coronary syndrome patients aimed to identify electrocardiographic findings detected by an AI model predicting coronary blood flow alteration. The aim of the study is to identify electrocardiographic findings detected by an automated artificial intelligence (AI) model that can predict coronary blood flow alteration as assessed by the TIMI grade flow at the very moment of the invasive coronary angiography in patients with acute coronary syndromes.
Adults (18 or older) with acute coronary syndrome undergoing clinically indicated invasive coronary angiography, with a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Accuracy of the AI-ECG TIMI AI Model
The primary endpoint is the AI-ECG TIMI model's ability to identify patients with actively occluded (TIMI 0-1) at the time of invasive coronary angiography using only single-standard 12-lead ECGs assessed by accuracy, sensitivity, specificity, positive, negative predictive values and F1 scores.
Time frame: Index hospitalization (assessed up to 5 days)
Subgroup Performance
AI-ECG TIMI AI Model's performance across subgroups 1. Demographic 2. Risk factors \& co-morbidities 3. Electrocardiographic 4. Culprit artery territory
Time frame: Index hospitalization (assessed up to 5 days)
Correlate established definitions of occlusion myocardial infarction (OMI) to myocardial perfusion status
2\. OMI definitions using routine angiographic and laboratory parameters will be correlated to abnormal myocardial perfusion using correlation coefficients.
Time frame: Index hospitalization (assessed up to 5 days)
ECG prediction of mechanical reperfusion
a. Correlation of AI-ECG TIMI model's raw numeric predictions (between 0 and 1) with myocardial perfusion grading post PCI.
Time frame: Index hospitalization (assessed up to 5 days)
Assessment of expert ECG interpretation blinded to all clinical information
1. Accuracy, sensitivity, specificity, positive and negative predictive value of expert interpretation of active OMI, reperfused OMI and entirety of OMI 2. Inter-rater variability of expert interpretation of active OMI, reperfused OMI and entirety of OMI.
Time frame: Index hospitalization (assessed up to 5 days)
STEMI-equivalent ECG patterns
a. Prevalence of STEMI equivalent ECG patterns and their correlation to TIMI flow grade at angiography.
Time frame: Index hospitalization (assessed up to 5 days)
Subgroup analysis of NSTEMI-OMI patients
9\. NSTEMI-OMI stratified according to immediate (\<2h) vs. SoC (\>2h) invasive management, median: i. Peak troponin (maximum rise before fall) ii. Median LVEF at discharge iii. Length of hospital stay iv. Length of cardiac care unit (CCU) or intensive care unit (ICU) stay v. Presence of life-threatening arrhythmias
Time frame: Index hospitalization (assessed up to 5 days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Sep 2026, 21 months.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 21 months is below that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2026 → Sep 2026 and completion May 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Powerful Medical